Insulet Corporation Stock

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 12:18:36 2024-05-23 pm EDT 5-day change 1st Jan Change
175.8 USD -2.90% Intraday chart for Insulet Corporation -4.88% -18.73%
Sales 2024 * 1.98B Sales 2025 * 2.34B Capitalization 12.68B
Net income 2024 * 228M Net income 2025 * 281M EV / Sales 2024 * 6.62 x
Net Debt 2024 * 420M Net Debt 2025 * 115M EV / Sales 2025 * 5.47 x
P/E ratio 2024 *
58.9 x
P/E ratio 2025 *
48.1 x
Employees 3,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.21%
1 week-4.02%
Current month+3.48%
1 month+6.37%
3 months-3.41%
6 months-5.34%
Current year-18.00%
More quotes
1 week
177.10
Extreme 177.1
188.97
1 month
160.19
Extreme 160.19
193.30
Current year
160.19
Extreme 160.19
217.46
1 year
125.82
Extreme 125.82
298.95
3 years
125.82
Extreme 125.82
335.91
5 years
105.92
Extreme 105.92
335.91
10 years
23.94
Extreme 23.94
335.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-07-30
Founder 54 13-12-31
Chief Tech/Sci/R&D Officer 53 18-12-31
Members of the board TitleAgeSince
Director/Board Member 57 17-08-09
Chairman 59 14-08-13
Director/Board Member 64 22-02-03
More insiders
Date Price Change Volume
24-05-23 176.2 -2.72% 159 943
24-05-22 181.1 -0.94% 675,297
24-05-21 182.8 -0.73% 739,587
24-05-20 184.1 -1.67% 585,580
24-05-17 187.3 +1.02% 723,372

Delayed Quote Nasdaq, May 23, 2024 at 10:16 am EDT

More quotes
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
181.1 USD
Average target price
233.5 USD
Spread / Average Target
+28.95%
Consensus